Claims

1. A method for:
   a) diagnosing dementia, or
   b) determining the risk of getting dementia in a subject that does not have dementia, or
   c) monitoring therapy or monitoring or guiding intervention in a subject that has dementia, or
   d) monitoring therapy or monitoring or guiding preventive intervention in a subject that is at risk of getting dementia,

   wherein the level of mature Adrenomedullin (ADM)-NH_2 according to SEQ ID No.: 4 is determined in a sample of bodily fluid of saida subject and wherein said level of mature ADM-NH_2 is compared with a threshold level,

   and wherein
   a) said subject is diagnosed with dementia if thesaid level of mature ADM-NH_2 according to SEQ ID No.: 4 is below said threshold level, or wherein
   b) said subject has an enhanced risk of getting dementia if said level of mature ADM-NH_2 according to SEQ ID No.: 4 is below said threshold level, or wherein
   c) the status of saida subject having dementia or being at risk of getting dementia is improving under preventive therapy or intervention if said level of mature ADM-NH_2 according to SEQ ID No.: 4 is increased during the course of preventive therapy or intervention and/or wherein intervention maybe continued if said level of mature ADM-NH_2 according to SEQ ID No.: 4 is increased above said threshold.

2. A method for:
   a) diagnosing dementia, or
   b) determining the risk of getting dementia in a subject that does not have dementia, or
   c) monitoring therapy or monitoring or guiding intervention in a subject that has dementia, or
   d) monitoring preventive therapy or monitoring or guiding preventive intervention in a subject that is at risk of getting dementia,

wherein a marker ratio is determined, the~~that maybe~~ marker ratio being the ratio of the level of mature ADM-NH_2 according to SEQ ID No.: 4 ~~determined in a sample of bodily fluid of said subject~~ to the level of pro-Adrenomedullin or a fragment thereof, ~~(~~which is not mature ADM-NH_2 according to SEQ ID No.: 4~~)~~, determined in a sample of bodily fluid of said subject,

and wherein said fragment of pro-Adrenomedullin is selected from a group comprising PAMP: SEQ ID No. 2, MR-proADM: SEQ ID No. 3, ADM-Gly: SEQ ID No.: 5 and CT-proADM: SEQ ID No. 6,

~~and~~ wherein said marker ratio is compared to a ratio threshold~~, ratio~~

and wherein

a) said subject is diagnosed with dementia if ~~the~~said marker ratio of mature ADM-NH_2/ pro-Adrenomedullin or a fragment thereof is below said ratio threshold, or wherein

b) said subject has an enhanced risk of getting dementia if ~~the~~said marker ratio of mature ADM-NH_2/ pro-Adrenomedullin or a fragment thereof is below said ratio threshold, or wherein

c) the status of ~~a~~said subject having dementia or being at risk of getting dementia is improving under therapy or intervention if said marker ratio is increased during the course of therapy or intervention,

or alternatively to ~~the above~~said marker ratio, the level of mature ADM-NH_2 according to SEQ ID No.: 4 ~~is determined in a sample of bodily fluid of said subject~~ and the level of pro-Adrenomedullin or a fragment thereof, ~~(~~which is not mature ADM-NH_2 according to SEQ ID No.: 4~~)~~, ~~is~~ are determined in a sample of bodily fluid of said subject, and both determined levels are combined in a mathematical algorithm, wherein the result of said mathematical algorithm is used for diagnosing dementia, or determining the risk of getting dementia in a subject that does not have dementia, or monitoring therapy or monitoring or guiding intervention in a subject that has dementia, or monitoring preventive therapy or monitoring or guiding preventive intervention in a subject that is at risk of getting dementia.

3. A method according to claim 1, wherein ~~the~~said threshold level of mature ADM-NH_2 according to SEQ ID No.: 4 is equal to or below 15 pg/ml~~, preferably equal or below 10 pg/ml, preferably equal or below 5 pg/ml~~.

4. A method according to claim 2, wherein ~~the~~said ratio threshold is in a range of 0.2 to 0.75~~, preferably 0.3 to 0.6, preferably 0.4 to 0.5~~.

5. A method according to any one of ~~the preceding~~ claims 1 to 4, wherein said sample of bodily fluid is selected from the group consisting of blood, serum, plasma, urine, cerebrospinal fluid (CSF), and saliva.

6. A method according to any one of claims 1 to 5, wherein the sample of bodily fluid is taken from a subject that has never had a diagnosis of dementia or mild cognitive impairment~~MCI~~ at the time of sample taking.

7. A method according to any one of ~~the preceding~~ claims 1 to 6, wherein said method is used for patient stratification to select a patient for treatment with an ~~A~~anti-adrenomedullin (ADM) antibody or ~~an~~ anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject, wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binds to the N-terminal part (aa 1-21) of adrenomedullin:
YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 21).

8. Use of an ~~A~~anti-adrenomedullin (ADM) antibody or ~~an~~ anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for the manufacture of a medicament for the~~use in~~ prevention ~~and~~ or therapy of dementia in a subject, wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binds to the N-terminal part (aa 1-21) of adrenomedullin:
YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 21).

9. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to claim 8, wherein said subject has a level of mature ADM-NH_2 according to SEQ ID No.: 4 determined in a sample of bodily fluid ~~of said subject~~ below a threshold level and/or has a marker ratio that is the ratio of the level of mature ADM-NH_2 according to SEQ ID No.: 4 determined in ~~a~~said sample ~~of bodily fluid of said subject~~ to the level of pro-Adrenomedullin or a fragment thereof determined in

~~a~~said sample ~~of bodily fluid of said subject~~ and wherein said marker ~~level~~ ratio is below a ratio threshold.~~,~~

10. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to claim 9, wherein~~,~~ said fragment of pro-Adrenomedullin is selected from ~~a~~the group consisting of~~comprising~~ PAMP (SEQ ID No. 2), MR-proADM (SEQ ID No. 3), ADM-Gly (SEQ ID No.: 5) and CT-proADM (SEQ ID No. 6).

11. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to any one of claims 8 to 10, wherein said subject is selected by a method according claim 7~~8~~.

12. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to any one of claims 9 to 11, wherein said~~the~~ threshold level of mature ADM-NH_2 according to SEQ ID No.: 4 is equal to or below 15 pg/ml~~, preferably equal to or below 10 pg/ml, preferably equal or below 5 pg/ml~~.

13. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to any one of claims 9 to 11, wherein ~~the~~said marker ~~level~~ ratio is in a range 0.2 to 0.75~~, preferably 0.3 to 0.6, preferably 0.4 to 0.5~~.

14. The use ~~Anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in prevention and therapy of dementia in a subject~~ according to any one of claims 8 to 13, wherein said subject is selected according to a method of claim 7 and, wherein ~~the~~said sample of bodily fluid is selected from the group consisting of blood, serum, plasma, urine, cerebrospinal fluid (CSF), and saliva.